chr1-44828037-G-A
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_003738.5(PTCH2):c.1864C>T(p.His622Tyr) variant causes a missense change. The variant allele was found at a frequency of 0.0118 in 1,614,188 control chromosomes in the GnomAD database, including 126 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. H622N) has been classified as Likely benign.
Frequency
Consequence
NM_003738.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PTCH2 | NM_003738.5 | c.1864C>T | p.His622Tyr | missense_variant | 14/22 | ENST00000372192.4 | NP_003729.3 | |
PTCH2 | NM_001166292.2 | c.1864C>T | p.His622Tyr | missense_variant | 14/23 | NP_001159764.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PTCH2 | ENST00000372192.4 | c.1864C>T | p.His622Tyr | missense_variant | 14/22 | 1 | NM_003738.5 | ENSP00000361266.3 | ||
PTCH2 | ENST00000447098.6 | c.1864C>T | p.His622Tyr | missense_variant | 14/23 | 1 | ENSP00000389703.2 |
Frequencies
GnomAD3 genomes AF: 0.00889 AC: 1354AN: 152236Hom.: 6 Cov.: 33
GnomAD3 exomes AF: 0.00947 AC: 2376AN: 250818Hom.: 24 AF XY: 0.00950 AC XY: 1288AN XY: 135624
GnomAD4 exome AF: 0.0121 AC: 17708AN: 1461834Hom.: 120 Cov.: 58 AF XY: 0.0119 AC XY: 8666AN XY: 727222
GnomAD4 genome AF: 0.00889 AC: 1355AN: 152354Hom.: 6 Cov.: 33 AF XY: 0.00863 AC XY: 643AN XY: 74494
ClinVar
Submissions by phenotype
not provided Benign:4
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Apr 01, 2022 | This variant is associated with the following publications: (PMID: 29230040) - |
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The PTCH2 p.His622Tyr variant was not identified in the Cosmic database but was identified in dbSNP (ID: rs11573586), ClinVar (reported by Invitae as benign for Basal cell nervus syndrome.), Clinvitae, MutDB (categorized as a polymorphism by SwissProt) and LOVD 3.0. The variant was identified in control databases in 2717 of 282218 chromosomes (26 homozygous) at a frequency of 0.009627 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: European (non-Finnish) in 2003 of 128572 chromosomes (freq: 0.01558), European (Finnish) in 315 of 25086 chromosomes (freq: 0.01256), other in 62 of 7220 chromosomes (freq: 0.008587), South Asian in 159 of 30616 chromosomes (freq: 0.005193), Ashkenazi Jewish in 42 of 10368 chromosomes (freq: 0.004051), African in 56 of 24968 chromosomes (freq: 0.002243), Latino in 78 of 35434 chromosomes (freq: 0.002201) and East Asian in 2 of 19954 chromosomes (freq: 0.0001). The variant was identified in a patient with rhabdomyosarcoma with a maternally inherited PTCH1 mutation and the p.H622Y PTCH2 mutation inherited paternally (Taeubner_2017_29230040). This variant was also identified in two patients with basal cell carcinomas, however these patients also had PTCH1 mutations (Skvara_2011_21430703). The p.His622Tyr residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | PTCH2: BS1, BS2 - |
not specified Benign:2
Benign, no assertion criteria provided | clinical testing | Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC) | - | - - |
Benign, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, Amsterdam University Medical Center | - | - - |
Basal cell carcinoma, susceptibility to, 1 Benign:1
Benign, criteria provided, single submitter | clinical testing | KCCC/NGS Laboratory, Kuwait Cancer Control Center | Jul 07, 2023 | - - |
Gorlin syndrome Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
PTCH2-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 18, 2020 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at